• All
  • Biotech
  • incubators & accelerators
  • innovation centres
  • Others
  • science parks
  • Tech
The Cambridge Science Park was established 52 years ago when Trinity College Cambridge embraced the concept that would change the hi-tech sector in Cambridge, the UK and beyond. Trinity owns the freehold of the Cambridge Science Park, which today comprises 150 acres, 1.7 million sq ft of high technology and laboratory buildings. It’s home to 7000 people at over 130 companies, ranging from exciting start-ups to some of the world's leading technology businesses.
The Bradfield Centre offers cutting-edge facilities designed to propel businesses to new heights. Their goal is to attract ambitious entrepreneurs and companies, both local and global, and provide them with scalable, state-of-the-art spaces. Through a collaborative culture, they connect them to investors, partners, mentors, and customers. Their accelerator programs cover diverse business and technical topics, aiming to grow Cambridge-based businesses exponentially.
Anglia Ruskin University is one of the largest universities in the East of England with campuses in Cambridge, Chelmsford and Peterborough as well as ARU London. ARU is an innovative global university with students from 185 countries coming to study with us.
The Babraham Institute performs world-leading research into the biological mechanisms underpinning ageing, development and the maintenance of health. We have three research focuses; Epigenetics - Studying modifications to DNA that affect gene activity, which helps to explain how our environment and lifestyle can affect our behavior or likelihood of getting diseases. Immunology - The study of the immune system, which helps to prevent disease in our bodies. Research in this area can lead to improvements in vaccines, combat autoimmune disease, develop tumour immunotherapy or improve the efficiency of organ transplantation. Signalling - Researching communication within and between the cells in our body, which underpins how cells and organs develop and respond to changes in their environment, vital for maintaining health.
Building on over 200 years of heritage, we are a major UK law firm located in the heart of Cambridge and six other cities across the country. Our office at Botanic House on Hills Road will be hosting 10 science and tech companies who will be waiting to meet and chat with you about their work.
The Babraham Research Campus is considered to be the UK’s leading campus to support early-stage bioscience enterprise and is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies with state-of-the-art laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.
Unity Campus is an exciting new urban innovation district in the heart of the Cambridgeshire countryside. Campus owners Howard Group, a Cambridge-based family business with a 50-year track record as a long-term property investor and developer, is transforming the site of a former tannery into a stunning modern workplace.
Founded in 1987, we are a sector-agnostic home for some 80 innovative companies: scaling-up, going international and raising risk capital. The Centre is set in extensive grounds within easy access of central Cambridge and has a popular restaurant and conference suite.
Innovate UK is the UK’s national innovation agency. They support business-led innovation in all sectors, technologies and UK regions. It help businesses grow through the development and commercialisation of new products, processes, and services, supported by an outstanding innovation ecosystem that is agile, inclusive, and easy to navigate.
ET Capital Limited, founded in 1992, is an investor in high-growth technology businesses based in southern England. The firm has raised and managed a series of funds focused on the globally significant cluster of science-based businesses around Cambridge, Oxford and London. Its first two funds, now closed, were backed by HSBC and the European Investment Fund.

At Illumina, our mission is to improve human health by unlocking the power of the genome. By delivering breakthroughs that redefine what's possible in genomics, we empower visionaries around the globe to uncover answers and make life-changing advances.
Enterprise is an area that clearly defines NatWest. As the UK’s biggest bank for business, we understand that SMEs are the lifeblood of the economy and that we have a responsibility to help them build back better. At the heart of our support for entrepreneurs is our comprehensive Accelerator programme including fully funded mentoring, insight and bespoke coaching, specifically designed to meet the needs of business owners who want to grow and scale their business, regardless of geographic location or sector.
The Cambridge Future Tech Venture Builder provides inventors, innovators and founders with the tools and collaboration required to succeed in building a DeepTech company.
We have Future Business Centres in Cambridge and Peterborough that offer flexible workspace, meeting rooms and networking, all within environmentally focused buildings – creating innovation communities for local businesses and social enterprises. Our expert programme team in East London work with local businesses to help them build resilience, grow and create positive impact.
Melbourn Science Park by Bruntwood SciTech offers world class office, laboratory and co-working space across the UK and is home to over 500 science and technology businesses. A 50:50 joint venture between Bruntwood and Legal & General, they create specialist working environments and provide support for businesses to start, scale and innovate. With science and technology ecosystems located in Manchester, Cheshire, Birmingham, Leeds, Liverpool and Glasgow, they acquired Melbourn Science Park, Cambridgeshire, in 2021. Plans have been submitted for a ten-year masterplan to redevelop the site into a globally recognised life science campus where research, innovation and manufacturing come together and change the future of human health. The Park will provide an inclusive place to work and socialise, promoting wellbeing and community for both local residents and businesses on the campus.
TusPark Holdings UK is a science and technology service corporation with an investment arm as a venture capital and private equity group fund. TUS has invested £250M+ in science and technology sector in the UK since 2018 and its investment portfolio spans in the era of life science/healthcare, digital technologies (big data, AI and IoT, etc.), new material, and environmental & new energy, with a unique model of "Incubation + Investment + cross-border M&As".
The Cambridge Judge Entrepreneurship Centre is where entrepreneurship gets real. It is where ground-breaking research and excellence in teaching combine to create global impact and enable entrepreneurs to turn ideas or innovations into real commercial applications and sustainable businesses. The Entrepreneurship Centre supports entrepreneurs and innovators at different stages from aspiration to venture creation and startup development, through to expansion and growth. We offer multiple entry points to resources, programmes and networks allowing individuals to structure and customise a personal journey directly relevant to them and their ventures.
Alchemab has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires. The platform uses well-defined patient samples, deep B cell sequencing, and computational analysis to identify convergent protective antibody responses among individuals that are susceptible but resilient to specific diseases.
Form the Future CIC connects young people to a world of career possibilities, inspires them to dream big and empowers them to fulfil their full potential.
Astex has built a rich product portfolio with multiple drugs in clinical development. Our research and development teams utilize our cutting edge technology platform in the relentless pursuit of innovative solutions that address the extensive and complex challenges in oncology and diseases of the CNS. is a synthetic biology company providing human cells for research, drug discovery and cell therapy. The company applies a patented safe harbour gene-targeting approach (opti-ox™; Pawlowski 2017) to inducibly express transcription factor combinations that reprogram human induced pluripotent stem cells (iPSCs) into highly defined and mature human cell types.
The Triple Chasm Model® is a unique new approach to drive successful commercialisation of innovation, delivering quantifiable impact. Underpinned by data from more than 3,000 scale-up companies around the globe.
Lives can be transformed when the strength of academia and business combine. As a biomedical institute, the Milner Therapeutics Institute acts as a catalyst and a driver, forming dynamic partnerships to unlock the power of emerging discoveries. The Milner encompasses both a research institute and a global outreach programme, which aims to transform pioneering science into therapies. The Institute is also home to the Frame Shift Bio-incubator, which provides space for start-ups and SMEs.
Part of the University of Cambridge, Cambridge Enterprise is responsible for supporting the translation of University research to create globally leading economic and social impact. We facilitate knowledge transfer by helping innovators, experts, and entrepreneurs to use commercial avenues to develop their ideas and expertise for the benefit of society, the economy, themselves, and the University.
Hear Glue Ear is an app designed for children aged 2-6 who are experiencing hearing loss due to glue ear. The app is available to download free of charge from the Apple and Android App Stores.
Crescendo Biologics Limited is a private, clinical-stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics. The lead programme, CB307, is a first-in-class PSMA x CD137 (4-1BB) bispecific molecule. Behind the lead programme, there is a pipeline of other first or best in class CD137 (4-1BB) bispecifics for the treatment of cancers, targeting MSLN, 5T4 and ROR1.
BugBiome is a biotech start-up that specializes in revolutionizing pest control through cutting-edge microbial science. The company focuses on the development of eco-friendly bio-repellents, ensuring effectiveness while prioritizing safety for humans, animals, and the environment. BugBiome's approach to sustainable pest management aims to contribute significantly to a healthier planet.
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living.
New Path Molecular specialises in the chemical synthesis of complex functional molecules using the cutting edge techniques, methods and instrumentation developed in the laboratories of Prof Steve Ley at the University of Cambridge. Our processes and molecules are being used to validate biological processes and produce products globally.
Mission Street was founded in 2017 as an independent investor, developer and operator of Science and Innovation real estate. The company has since established itself as an industry leader working in conjunction with a highly experienced Advisory Board who bring invaluable insight and expertise from the perspective of our customers.
Carbon-13 (13C) is a natural, stable isotope of carbon with a nucleus containing six protons and seven neutrons. They are the venture builder for the climate emergency, with a mission to reduce CO2e emissions by 400m tonnes through scalable climate tech ventures
Ethicronics main activity is hardware-enabled cybersecurity fighting against counterfeit and compromised electronics. Their first unique selling point is certifying your hardware is the one designed, at scale. Their SaaS solution provides hardware integrity certificates for market segments such as defence, security, transport, communication, finance and IoT.
Neurolentech was founded in late 2020 as a spin-out from IST Austria to identify new treatments for neurodevelopmental disorders. They use the latest scientific laboratory techniques to develop patient-derived neuronal cell models that give us insights into the molecular mechanisms of disease.
Deep Mirror is a team of leading experts at the interface of biology, physics, and machine learning, we are committed to bold innovation and on a clear mission: to elevate learning in the Life Sciences and power innovation in the century of biology.
Exonate is a biopharmaceutical company focused on the discovery and development of small molecule drugs that modulate alternative mRNA splicing to address diseases of high unmet medical need.
Kuano is focused on the discovery of new drugs with a novel AI and quantum simulation approach to finding better transition state-like inhibitors to overcome resistance by mutation. Kuano revolutionized this approach, once time-consuming and expensive, making it more rapid, cost-effective, and applicable to almost every therapeutic field.
Informetis creates value out of energy data. Their four technology pillars: Metis Device, Metis Cloud, Metis Engine and Metis App. Creating value out of energy data by utilising these unique tools, we call it Energy Informetis.
BioBeat connects entrepreneurs with biotech leaders. The annual summit challenges current thinking and the report selects 50 women trend setters.
At the Wellcome Genome Campus we undertake genome and biodata research. We provide bioinformatics services to the world and we deliver vital training in genomics and biodata to scientists and clinicians. We are at the interface of research and industry translating science into tangible societal benefits.
Nuclera: Rapid protein prototyping — it’s what we do. It’s what we deliver.
Rapid protein prototyping draws a straight line from theory to reality, allowing 
scientists to test hypotheses more efficiently. We understand that scientists need
access to protein prototyping on their own bench, on their own terms.
PhoreMost has developed a next-generation phenotypic screening platform called SITESEEKER® which can discern the best new targets for future therapies and, crucially, how to drug them. This has the potential to significantly increase the diversity of novel therapeutics for cancers and other disease of unmet need.
Enhanc3DGenomics' mission is to unlock the full potential of the human genome’s 3D organisation for target and biomarker discovery. They have expertise in developing an unparalleled platform integrating proprietary molecular biology technologies with machine learning to maximise the commercial potential of 3D genomics.
Creasallis was founded in 2021 by Zahra Jawad. It was created after the realization that innovation is limited in the pharmaceutical industry as the product pipeline dominates in this environment, and competition for resourcing and facilities is high. To make truly innovative drugs, start ups are needed to create that safe space to explore novel solutions.

We founded Kalium Health with the aim of providing real-world electrolyte data to transform the management of cardiorenal diseases. We have a world-class team, led by science and dedicated to medical product development. Our clinical focus is on kidney disease, heart disease and related chronic conditions where the cost of care is disproportionately high and the opportunity to improve health outcomes for a large population is great.
The Cambridge Crystallographic Data Centre (CCDC) are world-leading experts in structural chemistry data, software, and knowledge for materials and life sciences research and development. CCDC data, software, and services are trusted by academic and industrial institutions around the world with tens of thousands of active users from top 10 pharma to leading research institutions.
Cambridge Network is a membership organisation bringing people together through networking, learning, recruitment and events. We connect and support businesses, sparking collaboration within our vibrant network of over a thousand members.
Start Codon is a venture capital investor and venture builder based in Cambridge, England. We support aspiring entrepreneurs to spin out and/or help in the development and commercialisation of their disruptive innovations. In doing so, we aim to help them craft their vision into thriving companies that improve people’s lives and address unmet needs.
o2h co-work labs operates the mill scitech park in Hauxton, Cambridge, a place for entrepreneurs, scientists, techies & dreamers. Supported by high specification labs to create a genuinely unique environment for creativity and innovation to thrive.